Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
NCT07511543 on ClinicalTrials.gov · last registry update 2026-09-24
Registered but not yet open, with 100 participants planned. Due to report 31 October 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Feasibility - Recruitment. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 3 times since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Population Health Research Institute
- Sponsor type
- Other
- Enrollment
- 100
- Started
- 2026-10-31
- Primary completion
- 2028-10-31 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-14 | Reporting date moved | 2031-09-30 → 2028-10-31 35 months earlier |
| 2026-09-14 | Enrollment changed | 826 → 100 (-726) participants |
| 2026-09-14 | Record changed | P3 → P2 |
Primary outcome
Feasibility - Recruitment
Conditions studied
Ischemic Stroke
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.